Product Description
OCU410 is the second drug candidate from Ocugen's Modifier Gene Therapy Platform, which is expected to enter clinical trials in 2022. Ocugen recently announced a collaboration with CanSinoBIO for the chemistry, manufacturing, and controls ("CMC") development and manufacture of clinical supplies of OCU410 to advance the program. Modifier Gene Therapy is different from traditional gene augmentation. (Sourced from: https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-present-pre-clinical-data-ocu410-2nd-annual-dry-amd)
Mechanisms of Action: Gene Therapy, RORA
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: Orphan Drug - Stargardt DiseaseRegenerative Medicine Advanced Therapy - Geographic Atrophy|Macular Degeneration *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ocugen
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Ocugen announced they will present P2 Stargardt Disease results in 2Q27 for OCU-410
- Clinical Outcomes Expected - Ocugen announced they will present P3 Neovascular age-related macular degeneration|Stargardt Disease results in YE27 for OCU-410
- Clinical Outcomes Reported - Ocugen presented P1 Geographic Atrophy|Stargardt Disease results on 2026-10-01 for OCU-410
Highest Development Phases
Phase 3: Macular Degeneration|Stargardt Disease
Phase 2: Geographic Atrophy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06018558 |
ArMaDa | P2 |
Active, not recruiting |
Geographic Atrophy |
2026-02-03 |
39% |
2026-08-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT07770828 |
OCU410-301 | P3 |
Recruiting |
Macular Degeneration |
2028-07-30 |
2% |
2026-08-20 |
Primary Endpoints|Treatments |
NCT05956626 |
GARDian3 | P3 |
Active, not recruiting |
Stargardt Disease |
2026-09-28 |
2% |
2026-04-07 |
Primary Endpoints|Treatments|Trial Status |
